Avoidance is more easily incorporated and possible in the product design phase of the product, product design, and manufacturing process. This is because the product design phase is in the earlier developmental stage of the product lifecycle. This means changes can be made during this phase quite easily and is cheaper than if the changes were to occur during any other phase. It is also easier to incorporate avoidance in this phase because of the flexibility and iterative nature of this phase. 

I second to the fact that avoidance is easily incorporated in the product design phase due to multiple reasons, such as

1. During product design phase there are many changes to be made according to the practicality and feasibility of the product

2. It is often observed that after the initial draft of the design, the stakeholders, or the end users (clients) propose modifications, whether for cost-cutting considerations or additions to the product requirements.

3. Regulatory compliance and standards are often integrated into the product design phase, making it an opportune time to identify and mitigate risks associated with non-compliance.

Incorporating avoidance techniques in the product design phase is highly feasible and beneficial. This is mainly due to the fact that product design is the initial stage in the product development process, allowing for greater flexibility and cost-effectiveness in making changes compared to later stages like manufacturing. Designing a product requires the ability to envision and construct its structure, appearance, and purpose. This stage offers ample room for creative exploration, allowing for the consideration of various design options, potential challenges, and necessary adjustments without the pressure of financial or time limitations. A key aspect of product design entails an iterative process, where designs are continuously improved through feedback, testing, and validation. This approach facilitates early detection and resolution of any issues, reducing the risk of expensive mistakes or the need for significant revisions later on in the development process.

Of the three phases listed, avoidance is more effective and efficient in the product design phase. The main reason being is that product design decisions have the greatest significance on the overall outcome of the project. During the design phase, product ideas are developed into more refined concepts, therefore it's possible to address problems early on, which can prevent downstream complications in manufacturing and production. By identifying these issues early on, decisions can be made to mitigate or avoid them altogether. Another key aspect that the product design phase offers is a high degree of flexibility. As a result of its flexibility, designers are able to explore different design alternatives and solutions through given feedback. This, in turn, allows them to make adjustments to avoid potential pitfalls before finalizing the product specifications. Furthermore, addressing issues early on during the product design phase is generally more cost-effective than making changes later in the manufacturing process. Design modifications tend to be less expensive and disruptive compared to changes made during manufacturing, where tooling and production processes may need to be adjusted. Ultimately, while avoidance strategies can also be incorporated into the product and manufacturing processes, the product design phase offers the greatest opportunity to proactively address risks and avoid potential issues before they have a significant impact on the project.

I agree that risk avoidance is most effectively incorporated during the product design phase. One often overlooked advantage of this phase is the ability to leverage predictive risk analysis tools to proactively identify and eliminate potential hazards before they become embedded in the design. Using FMEA during the design process allows teams to evaluate potential failure points and address them before the product moves into manufacturing. DFM and DFR principles also help ensure that the chosen design minimizes risk and reduces the likelihood of manufacturing defects or performance failures later in the process. By using these strategies and others, companies can avoid risks rather than reacting to them in post-market phases.

Most of the discussion so far has been about avoidance, but I want to bring into question whether avoidance is actually the dominant strategy in medical device development. Avoiding risk sounds ideal in theory, but in reality, many medical devices exist because they work in high-risk spaces. Avoiding all risk would mean avoiding a bulk of innovation. However, some risk needs to be involved in order to advance in science and technology. 

For life-sustaining devices, for example, risk mitigation is more realistic than avoidance. You cannot avoid the variability that comes in biology, and you cannot avoid surgical technique differences. You cannot avoid changes in the environment or how effectively a patient adheres to medication or diet. However, you can control and monitor these risks. This is why post-market surveillance and risk management are so important in industry. 

Additionally, different risks are owned by different departments. Design risk is owned by R&D, process risk falls to operations, and post-market risk falls to quality and regulatory. Avoidance is easier where accountability is clear. For the business sector, avoidance could mean removing features and limiting performance. Labeling, training, and monitoring can mitigate risks instead, allowing these things to be incorporated into the device without enhancing risk. For manufacturing, sometimes accepting the risk is most feasible since the total cost of avoidance would outweigh the small risks when the risks are within the acceptance range. For different companies, there are different tolerances for risk as well. For smaller companies, risk is very volatile and could lead to disastrous outcomes for the company itself. However, larger companies can take the risk and have funds to spare in innovation. So, instead of asking where avoidance is the easiest, I think the bigger question is where avoidance is the most appropriate. When does avoidance strengthen a device, and when does it hinder a device’s true potential? Have you ever navigated this issue? 

@dev-doshi completely agree. I work in a medical device manufacturer. And for us, the name of the game isn't pure avoidance, but risk mitigation. By the time we start planning out the manufacture of a device, we're looking more at risk mitigation rather than risk avoidance. In order to reduce risk, once the product/process has been developed, we create PFMEAs. PFMEA stands for Process Failure Mode and Effects Analysis; this means analyzing where there is risk, what failures are possible, and how those can be mitigated in each process step. The reality is that this may look like increasing inspection frequency after certain process steps, using certain types of inspection equipment, or inspecting features that weren't specifically called out in the DSD.

@dev-doshi You make great points in avoidance, as it is not always the dominant or most appropriate strategy to use in the development of medical devices. If we truly avoided all risk, we would never build implantable devices, never develop life-sustaining medical devices and systems, and never push into spaces where the development of high sophisticated devices is essential for patient care. In a field such as this, innovation for new and effective technologies inherently operates in risk positive environments. Even when you look to actual regulations widely used in the field, such as ISO 14971; its objective itself to eliminate all risk, it is to reduce it to acceptable levels relative to the benefit of the device. I would refine your argument about avoidance slightly, as avoidance is strongest when the risk does not contribute to clinical benefit. If a feature introduces hazard without improving therapeutic value, avoidance is absolutely the right call. But when the risk is inseparable from the device's core function, mitigation and control is and should become the best path forward for further development. 

Then moving to your point about biology, you can't avoid physiological variability, user technique variation, or patient noncompliance. Those are environmental and human risk factors that are essential to take into account in these situations. Layered mitigation strategies become the basis of what a projects risk management should be, including design controls and monitoring, etc. for life-sustaining or implantable devices, where eliminating function to eliminate risks would defeat the entire purpose of the device.

I agree with Dev Doshi and Ehab B. that avoidance isn’t always the best strategy, especially for life-sustaining devices where eliminating risk could mean removing essential features. I’d add that avoidance works best in the design phase, while manufacturing and post-market processes benefit more from mitigation strategies, like PFMEAs. Combining early design avoidance with layered mitigation later ensures patient safety without stifling innovation. I’m curious how others prioritize which risks to avoid versus mitigate when timelines or resources are limited.

Avoidance is most easily incorporated during the product design phase. During the design phase the device is still conceptual, and hazards can be eliminated before they are built into the product. In addition, design changes at this stage are less costly than after validation has been completed or manufacturing has begun. Avoidance would be difficult or impossible in the manufacturing process. Most risk in manufacturing comes from human involvement and cannot be completely eliminated without compromising production efficiency. Mitigation strategies like training and process validation are more practical to reduce risk in manufacturing. Although avoidance is the most favored method of risk management, it is not always the best solution in the medical device industry. Some risks are inherent to a device’s intended use and removing a risk completely could eliminate the device’s purpose. For example, a scalpel that cuts tissue will always have some risk of the device user cutting or injuring themselves. Overall, effective risk management requires that avoidance, mitigation, and acceptance are used appropriately to ensure patient and user safety while maintaining a device’s functionality and intended use.